Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 3/20 | 0.31 |
| ▸ | HTR7 | P34969 | 3/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29568076 | 1.00 | JAK2 (0.32) | JAK2JAK3PTK2HTR1AHTR7 | |
| SCHEMBL24309890 | 0.89 | HTR1A (0.32) | HTR1AHTR7ALK | |
| SCHEMBL29566792 | 0.89 | HTR1A (0.32) | HTR1AHTR7ALK | |
| SCHEMBL24310367 | 0.86 | ALK (0.31) | ALK | |
| SCHEMBL29567020 | 0.85 | HTR1A (0.34) | JAK2JAK3PTK2HTR1AHTR7 | |
| SCHEMBL24310616 | 0.85 | HTR1A (0.34) | JAK2JAK3PTK2HTR1AHTR7 | |
| SCHEMBL29566802 | 0.84 | JAK2 (0.37) | JAK2JAK3PTK2ALK | |
| SCHEMBL24309714 | 0.84 | JAK2 (0.37) | JAK2JAK3PTK2ALK | |
| SCHEMBL24310022 | 0.83 | EGFR (0.35) | JAK3HTR1AHTR7 | |
| SCHEMBL26811513 | 0.82 | AURKA (0.36) | HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | JAK2 3498/4885JAK3 3929/4885PTK2 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.